NCT06789848View on ClinicalTrials.gov

Ligufalimab and Cadonilimab in Advanced Liver Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2030

Conditions
Advanced Hepatocellular CarcinomaRefractory Hepatocellular CarcinomaBiliary Tract Cancer
Interventions
DRUG

Ligufalimab

Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks

DRUG

Cadonilimab

Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks

Trial Locations (1)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Akesobio
All Listed Sponsors
collaborator

Akesobio

INDUSTRY

collaborator

Josephine Hughes Sterling Foundation

UNKNOWN

lead

University of Texas Southwestern Medical Center

OTHER

NCT06789848 - Ligufalimab and Cadonilimab in Advanced Liver Cancers | Biotech Hunter | Biotech Hunter